Pyxis Oncology appointed Thomas Civik as permanent Chief Executive Officer and Chairman of the Board, effective September 4, 2026, following his tenure as Interim CEO since February 2026. The company granted Mr. Civik a $100,000 sign-on bonus and a nonqualified stock option to purchase 2,503,050 shares with standard four-year vesting. John Flavin transitioned from Chairman to Lead Independent Director and Compensation Committee Chair. Concurrently, Dr. Santhosh Palani resigned from the Board for personal reasons, reducing board size to seven members; his unvested equity awards were fully accelerated. Pyxis Oncology is a clinical-stage biopharmaceutical company developing therapeutics for difficult-to-treat cancers.
